Humacyte, Inc. (NASDAQ:HUMA) Sees Significant Drop in Short Interest

Humacyte, Inc. (NASDAQ:HUMA) was the recipient of a large decrease in short interest in January. As of January 31st, there was short interest totalling 24,040,000 shares, a decrease of 6.2% from the January 15th total of 25,640,000 shares. Approximately 23.0% of the shares of the stock are sold short. Based on an average daily trading volume, of 4,330,000 shares, the days-to-cover ratio is presently 5.6 days.

Humacyte Stock Up 3.2 %

HUMA stock opened at $3.87 on Thursday. Humacyte has a twelve month low of $2.81 and a twelve month high of $9.97. The firm has a market cap of $487.08 million, a price-to-earnings ratio of -2.89 and a beta of 1.30. The business’s fifty day simple moving average is $4.44 and its two-hundred day simple moving average is $5.16.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in Humacyte by 85.2% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 202,825 shares of the company’s stock valued at $1,024,000 after buying an additional 93,283 shares during the period. Waverly Advisors LLC raised its stake in shares of Humacyte by 331.9% during the fourth quarter. Waverly Advisors LLC now owns 274,579 shares of the company’s stock valued at $1,387,000 after acquiring an additional 211,009 shares in the last quarter. Woodline Partners LP boosted its holdings in shares of Humacyte by 235.7% in the fourth quarter. Woodline Partners LP now owns 2,848,802 shares of the company’s stock valued at $14,386,000 after purchasing an additional 2,000,268 shares during the period. Squarepoint Ops LLC bought a new position in Humacyte in the fourth quarter worth approximately $132,000. Finally, ProShare Advisors LLC increased its holdings in Humacyte by 30.4% during the 4th quarter. ProShare Advisors LLC now owns 30,852 shares of the company’s stock worth $156,000 after purchasing an additional 7,188 shares during the period. 44.71% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Benchmark lifted their price target on Humacyte from $15.00 to $17.00 and gave the stock a “buy” rating in a research report on Monday, December 23rd. D. Boral Capital reiterated a “buy” rating and issued a $25.00 target price on shares of Humacyte in a report on Tuesday, January 21st. Finally, HC Wainwright restated a “buy” rating and set a $15.00 price target (up previously from $12.00) on shares of Humacyte in a report on Friday, December 20th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, Humacyte presently has an average rating of “Buy” and a consensus price target of $13.71.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.